In the original publication of this manuscript [Griesel R, Maartens G, Chirehwa M et al. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis; September 2020. https://doi.org/10.1093/cid/ciaa1073], the following grant was erroneously omitted from the article: National Research Foundation of South Africa (119078) and has been added to the article’s funding section. The authors regret this error.
. 2022 Jan 31;74(4):755. doi: 10.1093/cid/ciab804
Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Rulan Griesel
1,2, Gary Maartens
1,2,✉, Maxwell Chirehwa
1, Simiso Sokhela
3, Godspower Akpomiemie
3, Michelle Moorhouse
3, Francois Venter
3, Phumla Sinxadi
1,2
Rulan Griesel
1
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
2
Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Find articles by Rulan Griesel
Gary Maartens
1
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
2
Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Find articles by Gary Maartens
Maxwell Chirehwa
1
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Find articles by Maxwell Chirehwa
Simiso Sokhela
3
Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Find articles by Simiso Sokhela
Godspower Akpomiemie
3
Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Find articles by Godspower Akpomiemie
Michelle Moorhouse
3
Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Find articles by Michelle Moorhouse
Francois Venter
3
Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Find articles by Francois Venter
Phumla Sinxadi
1
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
2
Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Find articles by Phumla Sinxadi
1
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
2
Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
3
Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
✉
Correspondence: G. Maartens, Division of Clinical Pharmacology, Anzio Rd, Observatory 7925, South Africa (gary.maartens@uct.ac.za).
Collection date 2022 Feb 15.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC8886893 PMID: 35099526
This corrects the article "
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz" in volume 73 on page e3902.